Organigram (OGI) Q1 2025 Earnings Call Transcript
At this time, I would like to welcome everyone to the Organigram Holdings first-quarter fiscal 2025 earnings conference call. After the speaker's remarks, there will be a question-and-answer session.
Earnings call transcript: PennantPark's Q4 2024 earnings beat expectations
PennantPark Floating Rate Capital Ltd (NYSE:PFLT) reported its fourth-quarter 2024 earnings, surpassing analyst expectations with a net investment income of $0.37 per share, compared to a forecast of $0.
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js
Danaos Corporation (DAC) Q4 2024 Earnings Call Transcript
Danaos Corporation ( NYSE: DAC) Q4 2024 Earnings Conference Call February 11, 2025 9:00 AM ET Evangelos Chatzis - Chief Financial Officer John Coustas - Chief Executive Officer
Sonos (SONO) Q1 2025 Earnings Call Transcript
SONO earnings call for the period ending December 31, 2024. Sonos ( SONO 5.19%) Q1 2025 Earnings Call Feb 06, 2025, 4:15 p.m. ET
Proto Labs (PRLB) Q4 2024 Earnings Call Transcript
Proto Labs (NYSE: PRLB) Q4 2024 Earnings Call Feb 07, 2025, 8:30 a.m. ET
BP p.l.c. (BP) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 11, 2025 8:00 AM ETCompany ParticipantsCraig Marshall - Investor RelationsMurray Auchincloss
GoPro (GPRO) Q4 2024 Earnings Call Transcript
GoPro (NASDAQ: GPRO) Q4 2024 Earnings Call Feb 06, 2025, 5:00 p.m. ET Good afternoon. Thank you for attending today's GoPro fourth quarter 2024 earnings call. My name is Cole, and I will be the moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end.
Vertex Pharmaceuticals (VRTX) Sees Strong 2025 Revenue Growth
Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript
Arrowhead expects to receive a $500 million upfront payment in the next 10 days and has already received $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share.
Vertex Pharmaceuticals (VRTX) Misses Q4 Earnings Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.98 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $4.20 per share a year ago. These figures are adjusted for non-recurring items.
Earnings call transcript: Arvinas Q4 2024 surpasses EPS forecast, stock rises
Arvinas Inc. (ARVN) reported its earnings for the fourth quarter of 2024, revealing a smaller-than-expected loss per share ...
PetMed Express, Inc. (NASDAQ:PETS) Q3 2025 Earnings Call Transcript
Operator: Greetings and welcome to PetMed Express Third Quarter Financial Results Conference Call. At this time, all ...
As an Investor, Do You Really Have To Listen to Quarterly Earnings Calls?
Earnings calls provide key pieces of corporate information that can affect stock prices, and today there are shortcuts to save you the tedium.
Earnings call transcript: ProAct Q4 2023 sees revenue decline, positive outlook for 2025
ProAct, a $318 million market cap company, reported a decline in Q4 2023 revenue, with a 6.77% organic drop to SEK 1.3 billion. According to InvestingPro analysis, the stock appears undervalued ...
Radiant Logistics, Inc. (RLGT) Q2 2025 Earnings Call Transcript
Radiant Logistics, Inc. ( NYSE: RLGT) Q2 2025 Results Conference Call February 10, 2025 4:30 PM ET Elliot Alper - TD Cowen Mark Argento - Lake Street Capital Kevin Gainey - Thompson Davis Jeff ...
How AI Could Transform the Way You Listen to Earnings Calls
This AI-driven approach goes beyond traditional voice analysis methods by detecting nuanced vocal characteristics ...
IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:IRS) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript February 7, 2025 Santiago Donato: Good morning, everyone. I’m Santiago Donato, Investor ...